<=> <==========> US Biotechnology Moderna American Company has reached the final stage of experiments on a vaccine that may lead to the end of the Corona virus soon and its permanent disappearance from the world.

According to ArabiaNet, the company intends to start the final and collective phase of its experiments it is conducting on a new Corona virus vaccine, as it revealed that it will start next month to test the vaccine that it developed on 30,000 volunteers collectively to ensure that it is effective and ready to be put on the market.

A report of the British metro newspaper, which was seen by Al Arabiya Net, said that our company had got the green light to start the third stage of experiments, from the Food and Drug Administration, which will monitor the experiments. The results are closely related to making the appropriate decision about the vaccine.

The American company called the vaccine (mRNA-1273) and attracted volunteers from all over the United States to conduct its experiments. In the last stage, the 30,000 people will be injected. At a dose of 100 mg, then the results and the efficacy of the vaccine will be confirmed.

The American company, which is based in Cambridge in the state of Massachusetts, said that it will be able to produce more than one billion doses of vaccine annually starting from the beginning of next year 2021, This is in case the experiments currently under way are successful.

A company spokesman said that the main goal of this vaccine is to prevent the symptoms caused by the Covid-19 virus, and the company also confirms that it has chosen the dose that protects the person from being infected with the Coronavirus. Novelty while ensuring the minimum number of side effects that the vaccine can cause.

According to the information revealed by the British newspaper, the American company is currently working on the completion of the second phase of the experiments, in which 600 volunteers have already been given the vaccine and are being monitored for 28 days. These sixty people were injected with 100 mg doses and others with 50 mg of vaccine (mRNA-1273), and the company monitors the results with a focus on elderly people over the age of fifty.

All persons who were subjected to trials are to be kept under observation for a full year to ensure the effectiveness of the vaccine and that there are no side effects for it.

As soon as the news circulated about the company's approval to conduct the third and final phase of the experiments, its shares rose in the American markets, as it jumped by 6% on Thursday, and then continued the rise in trading Friday to close 3% higher ...